• Publications
  • Influence
Efficacy and long‐term toxicity of the rituximab‐fludarabine‐cyclophosphamide combination therapy in Waldenstrom's macroglobulinemia
Waldenstrom's macroglobulinemia is generally treated with alkylating agents, purine analogs and monoclonal antibodies, alone or in combination. We report the outcomes of 82 patients (median age 61Expand
  • 17
  • 1
Effect of immune modulation in relapsed peripheral T-cell lymphomas after post-allogeneic stem cell transplantation: a study by the Société Française de Greffe de Moelle et de Thérapie Cellulaire
Peripheral T-cell lymphoma carries a poor prognosis. To document a possible graft-versus-lymphoma effect in this setting, we evaluated the impact of immunomodulation in 63 patients with peripheralExpand
  • 5
  • PDF
A transition from using multi‐step procedures to a fully integrated system for performing extracorporeal photopheresis: A comparison of costs and efficiencies
The Pitié Salpêtrière Hospital Hemobiotherapy Department, Paris, France, has been providing extracorporeal photopheresis (ECP) since November 2011, and started using the Therakos® CELLEX® fullyExpand
  • 10
A phase II Bayesian sequential clinical trial in advanced Waldenström macroglobulinemia patients treated with bortezomib: interest of addition of dexamethasone
Abstract In patients with advanced Waldenström macroglobulinemia (WM), overall response rate (ORR) and median progression-free survival (PFS) achieved with bortezomib alone and bortezomib rituximabExpand
  • 3
Impact of plerixafor (mozobil) on hospital efficiency: A single center experience
Plerixafor (Mozobil) in combination with granulocyte colony‐stimulating factor (G‐CSF) has shown to increase mobilization of peripheral blood stem cells (PBSC) as compared to G‐CSF alone in patientsExpand
  • 5
Utilization of intravenous or subcutaneous immunoglobulins in secondary immune deficiency (ULTIMATE): A retrospective multicenter study.
INTRODUCTION We conducted a retrospective multicenter cohort study of patients receiving Immunoglobulin replacement therapy (IgRT) for secondary immune deficiency (SID) during 2012. METHODS DataExpand
Demyelinating polyradiculoneuritis in patients with multiple myeloma: the other side of bortezomib-induced neurotoxicity
Segolene Gendreau , Giulia Berzero , Camille Tafani, Igor Raynouard, Damien Ricard, Jean-Val ere Malfuson, Karine Viala, Rabab Debs, Caroline Houillier, Luca Diamanti, Enrico Marchioni, Timoth eeExpand